Literature DB >> 1620883

Localized extradural lymphoma: survival, relapse pattern and functional outcome. The Princess Margaret Hospital Lymphoma Group.

A J Rathmell1, M K Gospodarowicz, S B Sutcliffe, R M Clark.   

Abstract

Between 1967 and 1988, 22 patients were treated at The Princess Margaret Hospital (PMH) for localized (stage IE) non-Hodgkin's lymphoma (NHL) presenting with spinal extradural compression. The median age of the patients was 55 years (range 18-76). Back pain (20 patients) and leg weakness (18 patients) were the commonest complaints at presentation. Seven patients (30%) were non-ambulatory (paraplegic or severely paretic) and four had imparied sphincter function. Diffuse histiocytic lymphoma (12 cases) was the commonest histology. All patients initially had laminectomy decompression and were referred to PMH post-operatively. One patient (with coincident metastatic carcinoma of the breast) was treated palliatively. The remaining 21 patients received radical post-operative treatment: radiation therapy (XRT) alone in 12 cases (25-45 Gy), radiation therapy plus systemic combination chemotherapy (combined modality therapy, CMT) in 9 cases. The overall actuarial survival for the radically treated patients was 55% at 10 years and there was a significant difference (p = 0.037) between those treated by XRT alone (33%) and those who received CMT (86%). Only one patient from each treatment group failed locally but the distant recurrence-free survival for the XRT group was 32% compared to 100% for the CMT group (p = 0.017). One patient developed primary central nervous system (CNS) relapse. The functional results of treatment were excellent: 19 of the 21 radically treated patients regained or retained normal ambulatory status and the remaining two patients had only minor disability. Decompressive surgery and radiotherapy for localized extradural lymphoma ensures a high rate of local control and functional recovery.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1620883     DOI: 10.1016/0167-8140(92)90348-x

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  Primary bony non-Hodgkin lymphoma of the cervical spine: a case report.

Authors:  Zachary A Smith; Mark F Sedrak; Larry T Khoo
Journal:  J Med Case Rep       Date:  2010-02-02

Review 2.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

3.  An unusual instrumentation-related s1 radiculopathy in a patient treated for a primary vertebral (l3) lymphoma.

Authors:  Maurizio Iacoangeli; Alessandro Di Rienzo; Niccolò Nocchi; Lorenzo Alvaro; Maurizio Gladi; Roberto Colasanti; Nathalie Herber; Mauro Dobran; Massimo Scerrati
Journal:  Clin Med Insights Oncol       Date:  2012-11-19

4.  Primary spinal epidural lymphomas.

Authors:  Goutham Cugati; Manish Singh; Anil Pande; Ravi Ramamurthi; Mahalakshmi Balasubramanyam; Sumer K Sethi; Ajai Kumar Singh
Journal:  J Craniovertebr Junction Spine       Date:  2011-01

5.  Spinal extradural T-cell lymphoma with paraneoplastic hypereosinophilia in a dog: clinicopathological features, treatment, and outcome.

Authors:  Katie A McNaught; Joanna Morris; Kali Lazzerini; Caroline Millins; Roberto José-López
Journal:  Clin Case Rep       Date:  2018-04-06

6.  Primary epidural lymphocyte-depleted Hodgkin's lymphoma of the thoracic spine - presentation of a rare disease variant.

Authors:  Ekkehard M Kasper; Fred C Lam; Markus M Luedi; Pascal O Zinn; German A Pihan
Journal:  BMC Neurol       Date:  2012-08-03       Impact factor: 2.474

7.  Solitary lymphoblastic lymphoma of the thoracic spine.

Authors:  Dong Am Park; Sang Gon Park; Seok Won Kim
Journal:  J Korean Neurosurg Soc       Date:  2012-12-31

8.  Primary sacral non-Hodgkin's lymphoma: report of a case and systematic review of literature.

Authors:  Satya Vijay Chigurupati; Mridula Shukla; Manoj Pandey
Journal:  World J Surg Oncol       Date:  2021-02-24       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.